Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
暂无分享,去创建一个
M. Addo | A. Lohse | S. Jordan | D. Wichmann | S. Kluge | J. Schulze zur Wiesch | M. Lütgehetmann | S. Schmiedel | Dominik Nörz | M. Fischer | Marcel S. Woo | Andreas Heyer | T. Brehm
[1] Kamil H A Kim,et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge , 2022, The Journal of antimicrobial chemotherapy.
[2] H. van Bakel,et al. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.
[3] M. Aepfelbacher,et al. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants , 2022, Journal of Medical Virology.
[4] A. Cathcart,et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2022, JAMA.
[5] M. Aepfelbacher,et al. Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants , 2022, Viruses.
[6] Liyuan Liu,et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.
[7] S. Madhi,et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.
[8] P. Maes,et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern , 2021, bioRxiv.
[9] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[10] P. Pang,et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.
[11] M. Aepfelbacher,et al. Rapid Automated Screening for SARS-CoV-2 B.1.617 Lineage Variants (Delta/Kappa) through a Versatile Toolset of qPCR-Based SNP Detection , 2021, Diagnostics.
[12] M. Christner,et al. Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020 , 2021, Journal of clinical medicine.
[13] M. Addo,et al. Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza , 2021, Scientific Reports.
[14] M. Aepfelbacher,et al. Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with built-in screening functionality for del-HV69/70- and N501Y variants such as B.1.1.7 , 2021, Journal of Clinical Virology.
[15] anonymous. Update to living WHO guideline on drugs for covid-19 , 2020, BMJ.